ArticleCancer causes & control : CCC2010
Pooled analysis of the association of PTGS2 rs5275 polymorphism and NSAID use with invasive ovarian carcinoma risk.
Article in Cancer causes & control : CCC, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 7 syntheses or guidelines pooled it.
- The association between single nucleotide polymorphisms and ovarian cancer risk: A systematic review and network meta-analysis.Cancer medicine · 2023Pooled it
- Association between cyclooxygenase-2 (COX-2) 8473 T > C polymorphism and cancer risk: a meta-analysis and trial sequential analysis.BMC cancer · 2018Pooled it
- A splicing variant of TERT identified by GWAS interacts with menopausal estrogen therapy in risk of ovarian cancer.International journal of cancer · 2016Pooled it
- Risk and prognosis of ovarian cancer in women with endometriosis: a meta-analysis.British journal of cancer · 2014Pooled it
- Combined and interactive effects of environmental and GWAS-identified risk factors in ovarian cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2013Pooled it
- A meta-analysis of PTGS1 and PTGS2 polymorphisms and NSAID intake on the risk of developing cancer.PloS one · 2013Pooled it
- Meta-analysis on the association between non-steroidal anti-inflammatory drug use and ovarian cancer.British journal of clinical pharmacology · 2013Pooled it
- A framework for assessing interactions for risk stratification models: the example of ovarian cancer.Journal of the National Cancer Institute · 2023Article
- High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022Article
- Genetic Variation of Inflammatory Genes to Ischemic Stroke Risk in a Chinese Han Population.Pharmacogenomics and personalized medicine · 2021Article
- Estrogen Plus Progestin Hormone Therapy and Ovarian Cancer: A Complicated Relationship Explored.Epidemiology (Cambridge, Mass.) · 2020Article
- Association Between Menopausal Estrogen-Only Therapy and Ovarian Carcinoma Risk.Obstetrics and gynecology · 2016Article
- Polymorphisms in cyclooxygenase-2 gene in endometrial cancer patients.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Targeted immune therapy of ovarian cancer.Cancer metastasis reviews · 2015Review
- An association between the PTGS2 rs5275 polymorphism and colorectal cancer risk in families with inherited non-syndromic predisposition.European journal of human genetics : EJHG · 2013Article
- The immune system in the pathogenesis of ovarian cancer.Critical reviews in immunology · 2013Review
- SNPs in PTGS2 and LTA predict pain and quality of life in long term lung cancer survivors.Lung cancer (Amsterdam, Netherlands) · 2012Article
- Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies.The Lancet. Oncology · 2012Article
- Ovarian cancer risk associated with inherited inflammation-related variants.Cancer research · 2012Article
- The roles of beta-adrenergic receptors in tumorigenesis and the possible use of beta-adrenergic blockers for cancer treatment: possible genetic and cell-signaling mechanisms.Cancer management and research · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Inflammation is postulated to play an important role in ovarian carcinogenesis. Prostaglandin endoperoxide synthase 2 (PTGS2) is responsible for the conversion of arachidonic acid to prostaglandins in response to inflammation. In a pooled analysis of two population-based studies, the Hawaii Ovarian Cancer Case-Control Study and the New England Case-Control Study, including 1,025 women with invasive ovarian carcinoma and 1,687 cancer-free controls, the association of ovarian cancer risk with the PTGS2 rs5275 polymorphism and the use of nonsteroidal antiinflammatory drugs (NSAIDs) were examined. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using unconditional logistic regression. In the pooled analysis, the CC genotype was associated with a reduced risk of nonserous ovarian carcinoma (OR = 0.66; CI: 0.44-0.98). In addition, the lowest risk was observed among carriers of the CC genotype who were users of only nonaspirin NSAIDs (OR = 0.43; CI:0.20-0.93) in all women combined. The association of PTGS2 rs5275 with nonserous ovarian carcinoma and possible effect modification by NSAID use needs further validation, preferably in prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.